AU2011311946B8 - Polypeptides and their use in treating and limiting respiratory syncytial virus infection - Google Patents

Polypeptides and their use in treating and limiting respiratory syncytial virus infection Download PDF

Info

Publication number
AU2011311946B8
AU2011311946B8 AU2011311946A AU2011311946A AU2011311946B8 AU 2011311946 B8 AU2011311946 B8 AU 2011311946B8 AU 2011311946 A AU2011311946 A AU 2011311946A AU 2011311946 A AU2011311946 A AU 2011311946A AU 2011311946 B8 AU2011311946 B8 AU 2011311946B8
Authority
AU
Australia
Prior art keywords
polypeptide
rsv
seq
subject
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011311946A
Other languages
English (en)
Other versions
AU2011311946A1 (en
AU2011311946B2 (en
Inventor
Bruno E. Correia
William R. Schief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of AU2011311946A1 publication Critical patent/AU2011311946A1/en
Application granted granted Critical
Publication of AU2011311946B2 publication Critical patent/AU2011311946B2/en
Publication of AU2011311946B8 publication Critical patent/AU2011311946B8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011311946A 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection Ceased AU2011311946B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39059110P 2010-10-06 2010-10-06
US61/390,591 2010-10-06
PCT/US2011/055113 WO2012048115A2 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Publications (3)

Publication Number Publication Date
AU2011311946A1 AU2011311946A1 (en) 2013-05-02
AU2011311946B2 AU2011311946B2 (en) 2014-10-02
AU2011311946B8 true AU2011311946B8 (en) 2014-10-09

Family

ID=44993163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011311946A Ceased AU2011311946B8 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Country Status (7)

Country Link
US (1) US9718862B2 (https=)
EP (1) EP2625194B1 (https=)
JP (1) JP6023061B2 (https=)
CN (1) CN103282378B (https=)
AU (1) AU2011311946B8 (https=)
CA (1) CA2813752A1 (https=)
WO (1) WO2012048115A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9718862B2 (en) 2010-10-06 2017-08-01 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
HUE073526T2 (hu) * 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CA3066026A1 (en) 2017-06-14 2018-12-20 Virometix Ag Cyclic peptides for protection against respiratory syncytial virus
JP7550762B2 (ja) 2018-12-20 2024-09-13 ヴァイロメティックス アーゲー リポペプチドビルディングブロックおよび合成ウイルス様粒子
CN110853704B (zh) * 2019-11-11 2020-11-06 腾讯科技（深圳）有限公司 蛋白质数据获取方法、装置、计算机设备及存储介质

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
WO2002102303A2 (en) 2001-05-01 2002-12-27 Medimmune, Inc. Crystals and structure of synagis fab
CN1659187A (zh) 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
EP2062180A2 (en) 2006-08-25 2009-05-27 The Government of the United States of America as Represented by The Department of Health and Human Services Epitope-protein scaffolds and their use
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009100376A2 (en) 2008-02-07 2009-08-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antigenic cloaking and its use
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN103282378B (zh) 2010-10-06 2015-03-11 华盛顿大学商业中心 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9718862B2 (en) 2010-10-06 2017-08-01 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Also Published As

Publication number Publication date
US20130280262A1 (en) 2013-10-24
WO2012048115A2 (en) 2012-04-12
CN103282378B (zh) 2015-03-11
EP2625194A2 (en) 2013-08-14
WO2012048115A3 (en) 2012-06-21
AU2011311946A1 (en) 2013-05-02
CN103282378A (zh) 2013-09-04
EP2625194B1 (en) 2015-08-12
JP6023061B2 (ja) 2016-11-09
US9718862B2 (en) 2017-08-01
JP2014502143A (ja) 2014-01-30
CA2813752A1 (en) 2012-04-12
AU2011311946B2 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CA2902877C (en) Prefusion rsv f proteins and their use
US10858400B2 (en) Prefusion RSV F proteins and their use
AU2011311946B8 (en) Polypeptides and their use in treating and limiting respiratory syncytial virus infection
McLellan et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus
CN116096735A (zh) 乙型冠状病毒的预防和治疗
EP3677279A1 (en) Conformationally stabilized rsv pre-fusion f proteins
EP2834263B9 (en) Epitope-scaffold immunogens against respiratory syncytial virusm (rsv)
WO2021222639A2 (en) Recombinant human metapneumovirus f proteins and their use
US20250002907A1 (en) Stable coronavirus proteins and vaccine compositions thereof
WO2022232648A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
AU2021415906A1 (en) Stable coronavirus proteins and vaccine compositions thereof
Liang et al. Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2
WO2013152169A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection
US10766929B2 (en) De novo designed hemagglutinin binding proteins
CN121293297B (en) HIV nanoparticle vaccine
US20250090651A1 (en) Respiratory syncytial virus f proteins and nanostructures and uses thereof
US20250188131A1 (en) Viral proteins and nanostructures and uses thereof
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
CN121293297A (zh) 一种hiv纳米颗粒疫苗
WO2023138648A1 (zh) SARS-CoV-2刺突蛋白变体、其药物组合物及用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 39 , PAGE(S) 5388 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, APPLICATION NO. 2011311946, UNDER INID (72) CORRECT THE CO-INVENTOT TO CORREIA, BRUNO E.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired